News
Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...
Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...
Novo Nordisk has been losing big in the past year and is down over 66% from its peak in 2024. On the other hand, Eli Lilly ...
Novo Nordisk ( NVO -4.02%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...
Sales of Wegovy, launched locally in June, more than doubled to 5,000 units or 70 million rupees ($798,230) in July, the data ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback